MEET THE LEADERSHIP TEAM

A Diverse & Collaborative Group

Jeff Nemeth

Chief Executive Officer, Act Laboratories

 

After graduating from the Art Institute of Huston with a Fine Arts Degree in Photography in 1990, Jeff began his career as a photographer. Over time he built a successful business and at one point operating a total of seventeen studios.  Eventually selling his business to Lifetouch National School Studios.

 

After the sale of his successful photography business, Jeff took his first-hand experience with pain management after a car accident left him with chronic pain and his entrepreneurial spirit and began the process of creating Act Laboratories, Inc.  Jeff’s comprehensive knowledge of the cannabis industry and participation in advisory meetings, panel discussions, site visits, and frequent communications with regulators, have made him a valued leader and trusted resource for Department staff as they go about the challenging task of setting forth strong and sensible program guidelines.

Logan Morse

 Chief Business Officer, Act Laboratories

Logan comes to Act Laboratories with over twenty years of experience across multiple commercial roles while with Johnson and Johnson and a small biotech start-up business. He has held many executive level positions in the following areas sales, sales management, training, strategic marketing, and the commercial operations space. Logan brings a wealth of commercial experience to Act Laboratories while they continue to expand their national footprint.

David Isenga, MHSA

Scientific Advisory, Act Laboratories

David holds a Bachelor’s of Science in Chemistry from Wheaton College and a Master’s Degree from the University of Michigan’s School of Public Health. David has 19 years of analytical laboratory experience over a broad range of technologies and platforms, working in both the public and private sectors.

 

Over the past 8 years, David has worked closely with others in the cannabis industry to develop and validate analytical methods for all of the major tests which ACT currently offers. In addition to his extensive bench experience, he is a specialist in the area of ISO 17025:2005 accreditation, and has helped ACT to achieve the largest accredited scope of testing currently found within the U.S. cannabis industry.

Robert Sheroff

Scientific Advisory, Act Laboratories

Robert received his Bachelor of Science Pharmacy degree from Rutgers University College of Pharmacy and an MBA in Pharmaceutical Marketing from Fairleigh Dickinson University. With over twenty-five years of experience at Johnson and Johnson alone, Robert has extensive experience in supply chain management and has successfully led global organizations in both small and large molecule manufacturing and quality responsibility.  He also has a strong reputation with the FDA and other regulatory agencies.

Currently, Robert is the President of RMMTC, LLC, a pharmaceutical supply chain consulting firm supporting small and mid-sized companies. He serves as a non-executive director on the Board of DPS Engineering Holdings Limited and through consulting and teaching explores ways to streamline the CMO/CDMO role within the pharmaceutical industry.

Howard Goodwin, M.D.

Scientific Advisory, Act Laboratories

 

After achieving his B.A. from Princeton University, Howard Goodwin received his medical degree from Jefferson Medical College in 2001.  Dr. Goodwin has served as an investment professional in the healthcare equity market for 18 years. Previously, Dr. Goodwin was the healthcare sector head at Miura Global (Tiger fund) and the medical devices and life-sciences sector head at Citadel Investments. Dr. Goodwin developed a disciplined investment process and risk/reward framework as a senior analyst at Maverick Capital and as an analyst at Graham Partners.

 

Most recently, as a portfolio manager at Millennium Partners, Dr. Goodwin ran a long/short healthcare equity portfolio, where he managed all aspects of the investment process including selection of individual investments as well as risk management across the portfolio.  During his investing career, he has covered the entire spectrum of healthcare segments including pharmaceutical, medical devices, services, and alternative healthcare markets. As a co-founder of Intrinsic Capital Partners, Dr. Goodwin has extensively researched and developed a broad network across the medical cannabis market.

 

Bob Miller, Ph.D.

Scientific Advisory, Act Laboratories

Serving as the Senior Vice President of Quality at Gilead Sciences Inc. Bob Miller, Ph.D. has a wealth of experience in the design and implementation of quality systems and guiding companies actively engaged in quality and compliance enhancements in response to FDA and other global regulatory agencies. He holds a Bachelor of Science in Pharmacy and a Ph.D. in Pharmaceutical Chemistry from Rutgers University College of Pharmacy. 

During his career, Bob has gained experience in diverse product portfolios including sterile, solid and liquid dosage forms, APIs, Rx, and over the counter products working with major global, national and international Pharma and Generic companies such as Bayer Pharmaceutical Corporation, Pfizer/Warner-Lambert, and Johnson & Johnson.

Matt Westfall, Ph.D.

Scientific Advisory, Act Laboratories

 

Matt Westfall, Ph.D., joined ACT Laboratories in May 2019 as VP, Lab Operations and has taken on a leading role in the establishment of the company’s multiple laboratory testing locations and the testing platforms being implemented. In this capacity, Dr. Westfall will be responsible for all laboratory operations as well as directing R&D activities for new assay and platform development.

 

Previously at Pierian Biosciences Matt served as Director of Assay Development and Lab Operations and had a leading role in the establishment of the company’s ChemoINTEL™ and ImmunoINTEL™ platforms serving both Operations and R&D. Dr. Westfall served a similar role with Nodality, Inc. as Director of Assay Development where he was involved in the development of novel cytometric assays, the internal implementation of new technologies and instrument platforms, and external scientific collaborations. Prior to joining Nodality, he spent several years working for Esoterix, a Division of LabCorp Clinical Trials.  During that time, Dr. Westfall directed various operations and R&D organizations in the US and Europe, developing and operationally implementing custom assays supporting drug discovery, early and late phase clinical trials, and clinical diagnostics.

 

Dr. Westfall earned a BS in Biology from Rhodes College and a Ph.D. in Biochemistry from Vanderbilt University.

John VanOosendorp V

Financial Advisory, Act Laboratories

 

John VanOosendorp V is leading the financial team as Controller with Act Laboratories. With a Bachelor's degree from Siena Heights University in Accounting, and an MBA in Business Management/Finance from Franklin University, John has over a decade of experience in costing, cash-flow analysis, compliance, forecasting/budgets, accounts payable and receivables,financial software implementations, month-end close, payroll, and was a certified SOX auditor at Lear Corporation.  

 

Over his career, John has worked in the finance department of companies such as Lear Corporation, Dart Container, and Gestamp. Under his direction as CFO, Jetech, Inc. was able to improve their EBIDTA by 14%, thru an improved supply-chain management system, purchasing objectives, and aided in pricing strategies. He also minimized audit risks and built a corporate business plan that saw exponential growth in annual revenue in just three years.

Cornelius Merlini

Financial Advisory, Act Laboratories

 

Cornelius Merlini has over thirty years of life science experience across a wide array of functions and across all sectors within healthcare. Prior to founding Intrinsic Capital Partners, LLC, a growth equity firm focused on investing in market-leading life-science and technology companies within the global cannabis industry, Mr. Merlini was General Manager of HealthTronics Lab Solutions, the diagnostic division within Endo Pharmaceuticals.  He successfully transformed this business through strengthening the infrastructure and driving hyper growth which ultimately led to the sale of HLS to Metamark Genetics which he oversaw. Prior to Endo, Mr. Merlini was SVP, Commercial Operations at Cord Blood Registry, a market leader in cord blood stem cell banking. In his four years at CBR, sales doubled from $60mm to $125mm and market share grew to over 50%. He participated in a successful exit when GTCR bought CBR in 2012.  

 

Mr. Merlini spent ten years with increasing marketing, management and franchise leadership responsibilities at Johnson & Johnson. He spent five years in the consumer sector where he ran J&J’s US Nutritional Franchise and five years at Centocor where he served as Worldwide Vice-President of the cardiovascular franchise for Johnson & Johnson's biopharmaceutical business. In this capacity, he was responsible for the entire CV portfolio from Discovery through Marketing and all business development. His team was responsible for licensing in Xarelto into Johnson & Johnson.  Earlier in his career, Mr. Merlini spent ten years at Marion Laboratories (now Sanofi) where he had a long track record of success in sales and sales leadership positions. Mr. Merlini has a B.S. in Finance from Villanova University.

Please reload

    ©2018 BY ACT LABORATORIES. ALL RIGHTS RESERVED